Detalhe da pesquisa
1.
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.
Lung Cancer Manag
; 9(1): LMT28, 2020 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32256712